Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 9/20 | 0.46 |
| ▸ | HRH2 | P25021 | 1/20 | 0.46 |
| ▸ | HRH1 | P35367 | 1/20 | 0.46 |
| ▸ | BACE1 | P56817 | 4/20 | 0.45 |
| ▸ | METAP2 | P50579 | 2/20 | 0.44 |
| ▸ | PIM1 | P11309 | 1/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11713412 | 0.77 | HRH3 (0.56) | HRH3BACE1 | |
| SCHEMBL5014778 | 0.76 | HRH3 (0.45) | HRH3HRH2HRH1BACE1METAP2 | |
| SCHEMBL27961380 | 0.75 | HRH3 (0.45) | HRH3BACE1 | |
| SCHEMBL3874659 | 0.75 | HRH3 (0.53) | HRH3BACE1 | |
| Hydrochloric Acid SCHEMBL3876019 | 0.74 | HRH3 (0.52) | HRH3BACE1 | |
| SCHEMBL17678283 | 0.73 | HRH3 (0.43) | HRH3BACE1PIM1 | |
| SCHEMBL17527302 | 0.73 | HRH3 (0.43) | HRH3BACE1 | |
| SCHEMBL5929400 | 0.73 | RAD52 (0.54) | HRH3BACE1 | |
| SCHEMBL17678060 | 0.73 | BACE1 (0.44) | HRH3BACE1 | |
| Hydrochloric Acid SCHEMBL5929401 | 0.72 | RAD52 (0.53) | HRH3BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7943639-B2 | Such as 6-benzenesulfonyl-4-piperazin-1-yl-quinoline hydrochloride; for treatment of central nervous system and/or 5- HT6 receptor related disorders; for weight gain/loss | PROXIMAGEN LIMITED (GB) | 2011-05-17 | — | — | US | disclosed |
| US-20100222330-A1 | New Compounds | BIOVITRUM AB (SE) | 2010-09-02 | — | — | US | disclosed |
| US-7572787-B2 | Substituted naphthalene sulfonamides | BIOVITRUM AB (SE) | 2009-08-11 | — | — | US | disclosed |
| US-20070066598-A1 | Compounds | BIOVITRUM AB, A SWEDEN CORPORATION | 2007-03-22 | — | — | US | disclosed |
| US-20070066599-A1 | New compounds | BIOVITRUM AB, A SWEDEN CORPORATION | 2007-03-22 | — | — | US | disclosed |
| US-7144883-B2 | Bicyclic sulfonamide compounds | BIOVITRUM AB (SE) | 2006-12-05 | — | — | US | disclosed |
| US-20040024210-A1 | New compounds | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2004-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066599-A1 | New compounds | SULT2A1, GPR119, STS | HRH3 3244/4885HRH2 1638/4885HRH1 2300/4885 |
| US-20070066598-A1 | Compounds | SULT2A1, STS, SLC5A2 | HRH3 2634/4885HRH2 1120/4885HRH1 2043/4885 |
| US-20040024210-A1 | New compounds | SULT1E1, SULT2A1, SULT1A1 | HRH3 3793/4885HRH2 2845/4885HRH1 3828/4885 |
| US-20100222330-A1 | New Compounds | SULT2A1, GPR119, STS | HRH3 3244/4885HRH2 1638/4885HRH1 2300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.